Walter Alexander, Medical Writer

A study recommends use of trastuzumab concurrently with the taxane portion of chemotherapy for breast cancer patients.

In the BIG 1-98 trial, high-risk patients did best with 5 years of letrozole and low-risk patients did similarly well with any of the trial%u2019s regimens.

Letrozole treatment over 5 years was still associated with significantly better overall survival than 5 years with tamoxifen.